Alerta De Seguridad para Product name: Estradiol Life II Technical Name: Estradiol Life II ANVISA Registration Number: 10158120172 Hazard Class: I Affected Model: Affected serial numbers: Lot: 1004403350, 1004343690, 1004490710, 1004661480, 1004666000.

Según Agência Nacional de Vigilância Sanitária (ANVISA), este evento ( alerta de seguridad ) involucró a un dispositivo médico en Brazil que fue producido por bioMérieux Brasil S.A.; bioMérieux S.A.

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Safety alert
  • ID del evento
    2172
  • Fecha
    2016-08-12
  • País del evento
  • Fuente del evento
    ANVISA
  • URL de la fuente del evento
  • Notas / Alertas
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Notas adicionales en la data
    1- Sending a letter to the usual customers / distributors of the product (Annex to this Notice) with the guidelines necessary to use the product. 2- See the step-by-step action plan that will be developed to notify all customers until the manufacturer includes in the instructions for use the risk of cross-reaction of the Vidas Estradiol II kit with the drug Fulvestrant.
  • Causa
    Biomérieux sa france manufacturer of the product vidas estradiol ii, was contacted by the national agency for the safety of medicines and products for health of france - ansm; to verify the occurrence of cross-reaction of the kit in question, or other kits for dosing estradiol, with the product fulvestrant. this request came from the fact that ansm was informed of this occurrence with a siemens healthcare company product. based on ansm's report, biomérieux sa opened an internal investigation (pr965756) and a study was carried out with the vidas family of equipment (vidas, mini-vidas and vidas3) together with the vidas estradiol ii kit, the only test for estradiol by biomérieux sa the investigation concluded that fulvestrant is cross-reactive with the vidas test. the cross-reactivity study done according to the principles of the clsi guide ep7-a2 "interference test in clinical chemistry" guide approved second edition, demonstrated that the cross-reactivity percentage obtained for fulvestrant is a maximum of 0.32% for a drug concentration of 20,000pg / ml.
  • Acción
    Field Action Code FSCA 3039 triggered under the responsibility of the company bioMérieux Brasil SA Company will inform the clients.

Manufacturer